This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

DUBLIN--(BUSINESS WIRE)--The "AI in Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for AI in biotechnology was valued at $3.8 billion in ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher Scientific, unpacks the evolving landscape of precision therapeutic and ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. The Cambridge, Massachusetts-based biotech is also laying off staffers and CEO Keith ...

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other ...

Brandeis University has named University of California, San Francisco (USCF) professors James A. Wells and Kevan M. Shokat as the 2025 recipients of the Jacob and Louise Gabbay Award in Biotechnology ...

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the ...

From Adelaide to San Francisco, the biotechnology landscape is shifting – and, in some cases, straining under the weight of ...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...

We’re hoping to see more early-stage funding in 2026 to help newer companies get off the ground. The public market, especially IPOs, has been a bit slow, with only 11 companies going public in 2025, ...

Disc Medicine, Inc. is a biotechnology company specializing in the development of innovative therapies for hematologic diseases. Its strategy centers on leveraging scientific expertise in red blood ...